What interviewers actually evaluate

Abbott Laboratories marketing interviews test whether candidates understand how marketing across a four-segment healthcare portfolio – medical devices, diagnostics, established pharmaceuticals, and nutritionals – requires fundamentally different marketing models for each segment while drawing on shared brand equity and commercial capabilities that Abbott applies across its portfolio. FreeStyle Libre marketing operates in a high-growth CGM category where Abbott must simultaneously run direct-to-consumer campaigns targeting the tens of millions of type 2 diabetes patients who have not yet started CGM, healthcare provider marketing targeted at endocrinologists and primary care physicians who control CGM prescription access, and payer access marketing that positions Libre as cost-effective diabetes management for formulary inclusion, where Libre's competition against Dexcom requires marketing that clearly differentiates on clinical utility, ease of use, and total program value rather than competing primarily on price. Diagnostics marketing serves hospital and reference laboratory customers through a professional B2B model where Alinity platform positioning is built through scientific publications, clinical conference presence, and laboratory director relationship development rather than consumer advertising. Established Pharmaceuticals marketing in emerging markets serves local healthcare systems with branded generics positioned on manufacturing quality, brand heritage, and reliability rather than the clinical differentiation marketing that characterizes innovative pharmaceutical products. Nutritionals marketing spans DTC consumer campaigns for Ensure and Pedialyte (competing in grocery and pharmacy retail channels) and clinical marketing for healthcare professional recommendations of Abbott's therapeutic nutrition products. Marketing at Abbott spans FreeStyle Libre consumer and HCP integrated marketing (where building CGM adoption requires a coordinated push strategy targeting physicians and a pull strategy creating patient awareness that pulls patients to request CGM from their healthcare providers), competitive CGM positioning and Dexcom differentiation (where Abbott's consumer and clinical marketing must clearly communicate what Libre offers that Dexcom does not in terms of wear experience, sensor accuracy, and total diabetes management program value), Alinity professional and scientific marketing for diagnostics (where laboratory director marketing through peer-reviewed publication support, conference scientific programming, and opinion leader development drives Alinity platform adoption), and consumer brand marketing for Abbott Nutrition (where Ensure's campaign targeting older adults, Pedialyte's expansion beyond pediatric into adult hydration, and Similac's brand rebuilding after the formula crisis each require distinct consumer marketing strategies).

Start your free Abbott Laboratories Marketing practice session.

What interviewers actually evaluate

FreeStyle Libre DTC and HCP Integration, Dexcom Competitive Positioning, and Multi-Segment Marketing Model Management

Abbott marketing interviews probe whether candidates understand how healthcare portfolio marketing differs from single-segment marketing in the integrated push-pull marketing model for CGM (the FreeStyle Libre expansion into type 2 diabetes requires coordinated HCP marketing that changes physician prescription behavior alongside DTC marketing that creates patient awareness and demand – push without pull creates physician willingness without patient requests, while pull without push creates patient interest that physicians don't fulfill because their prescribing practice hasn't changed, and marketing professionals who can design and sequence integrated push-pull campaigns that change both physician and patient behavior simultaneously will drive CGM adoption more efficiently than those who focus on only one side of the access equation), the regulatory constraint on healthcare DTC advertising (FDA's advertising regulations for medical devices and drugs require that marketing claims be consistent with cleared indications, balanced with risk information, and substantiated by clinical evidence – marketing professionals who understand how to create compelling DTC and HCP marketing within these FDA constraints, rather than applying general consumer marketing principles without regulatory review, will build campaigns that achieve regulatory approval without extended review delays), and the multi-segment marketing model management (Abbott's four segments require marketing professionals who understand that the Alinity marketing model – built on scientific publications, laboratory conference presence, and KOL development – is completely different from the Ensure consumer marketing model, and who can manage their segment's specific marketing model rather than applying a single framework across the portfolio).

The Similac brand recovery marketing dimension requires understanding that the 2022 infant formula crisis required Abbott to simultaneously address immediate consumer safety concerns through factual crisis communication while developing a longer-term brand recovery strategy that rebuilt parent and healthcare provider trust in Similac's quality and safety after the voluntary recall and facility shutdown.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
FreeStyle Libre push-pull marketing integration	Do you understand how to design the integrated HCP and DTC marketing program for FreeStyle Libre type 2 diabetes expansion – how to sequence physician education campaigns that change prescribing behavior alongside consumer awareness campaigns that create patient demand, what the measurement framework looks like for tracking whether HCP and patient marketing is jointly moving CGM adoption rates in the type 2 population, and how to identify and prioritize the physician specialties and patient segments where integrated marketing investment generates the highest CGM adoption yield? We flag marketing answers that describe CGM marketing as either pure HCP professional marketing or pure DTC without engaging with the integrated push-pull design that drives adoption in a market where both physician prescription and patient demand are necessary for category growth.	HCP prescribing behavior change campaign design for type 2 CGM, DTC patient awareness campaign design for type 2 CGM demand creation, push-pull campaign sequencing and adoption rate measurement
Dexcom competitive positioning and FreeStyle Libre differentiation	Can you describe how to develop Abbott's competitive marketing positioning for FreeStyle Libre against Dexcom in type 1 diabetes – how to identify the differentiated clinical and user experience attributes that represent genuine Libre advantages for specific patient segments, what the claim substantiation requirements look like for comparative effectiveness statements that must be cleared for use in FDA-regulated device promotion, and how to design the HCP sales aid that communicates Libre's differential value proposition in a way that is compelling to endocrinologists who are familiar with both competing platforms? We score whether your competitive marketing approach engages with the regulatory substantiation requirements and segment-specific differentiation analysis that distinguish compliant medical device competitive marketing from unregulated consumer product positioning.	FreeStyle Libre versus Dexcom clinical and user experience differentiation by patient segment, comparative claim substantiation requirements for FDA-regulated device promotion, HCP sales aid design for endocrinologist competitive messaging
Alinity professional marketing and laboratory KOL development	Do you understand how to build Alinity's professional marketing program for hospital and reference laboratory customers – how to develop the clinical publication strategy that generates peer-reviewed evidence supporting Alinity performance claims, what the laboratory director KOL program looks like for identifying and engaging the scientific opinion leaders whose presentations at AACC and CAP conferences influence laboratory director purchasing decisions, and how to design the product launch marketing program for a new Alinity assay menu addition that positions the new test as a clinical improvement over the incumbent testing methodology? We detect marketing answers that describe diagnostics marketing as trade show attendance without engaging with the scientific communication strategy and KOL development that distinguish professional laboratory marketing from consumer marketing.	Clinical publication strategy for Alinity performance evidence generation, laboratory KOL identification and engagement for conference-based peer influence, new assay launch marketing for clinical differentiation versus incumbent methodology
Consumer brand marketing for Abbott Nutrition	Can you describe how to develop the consumer marketing strategy for Ensure's adult nutrition positioning – how to identify the consumer insight that drives purchase decision in the adult oral nutritional supplement category (where the primary purchaser may be an adult managing their own nutrition or a caregiver purchasing for an older family member), what the channel strategy looks like for reaching grocery and pharmacy retail customers alongside clinical recommendations from healthcare providers, and how to measure the contribution of consumer advertising versus healthcare professional recommendation to Ensure purchase occasions? We flag marketing answers that describe nutritional product marketing as food advertising without engaging with the healthcare brand credibility and clinical recommendation channel that distinguish Ensure from mainstream consumer food brands.	Adult nutrition consumer insight for Ensure brand positioning, retail and clinical channel marketing integration for nutritional product reach, healthcare professional recommendation versus consumer advertising contribution measurement

How a session works

Step 1: Choose an Abbott Laboratories marketing scenario – FreeStyle Libre push-pull HCP and DTC marketing integration, Dexcom competitive positioning and Libre differentiation, Alinity professional marketing and laboratory KOL development, or Abbott Nutrition consumer brand marketing strategy.

Step 2: The AI interviewer asks realistic Abbott marketing questions: how you would design the 18-month integrated marketing plan to drive FreeStyle Libre CGM adoption in the type 2 diabetes primary care physician market, including what the HCP educational program curriculum covers, what the DTC campaign strategy is for reaching type 2 patients in their media environment, and how you measure whether the integrated campaign is driving new CGM patient starts; how you would advise Abbott's marketing team on whether a proposed TV commercial claiming that FreeStyle Libre achieves "superior accuracy" compared to a fingerstick glucose meter is appropriate to run without modification, including what FDA claim substantiation requirements apply and what evidence would be required to support a superiority claim in regulated medical device advertising; or how you would develop the Similac brand recovery marketing strategy for the 18 months following the Sturgis facility restart, including how you sequence the safety communication, what the claims development process looks like for asserting quality standards, and how you measure whether brand trust metrics are recovering.

Step 3: You respond as you would in the actual interview. The system scores your answer on CGM push-pull marketing integration, competitive positioning claim substantiation, Alinity scientific marketing, and Abbott Nutrition consumer marketing.

Step 4: You get sentence-level feedback on what demonstrated genuine Abbott healthcare portfolio marketing expertise and what needs stronger FDA claim substantiation specificity or integrated push-pull campaign sequencing.

Frequently Asked Questions

How does FDA regulate medical device and nutritional product advertising?
FDA regulates advertising and promotional materials for medical devices under the FD&C Act and 21 CFR Part 801. Device promotional materials must be consistent with the cleared or approved labeling, cannot make claims for uses not covered by the clearance, and must present a fair balance of benefits and risks when risk information is required. For FreeStyle Libre, this means promotional claims about accuracy, ease of use, and clinical benefits must be substantiated by the clinical evidence submitted for clearance. Comparative claims against Dexcom require substantiation evidence supporting the comparison. Abbott Nutrition's infant formula and other nutritional products are regulated as foods, with different advertising standards – FDA has authority over health claims and structure/function claims on nutritional product labels, and FTC has authority over nutritional product advertising to consumers.

How does FreeStyle Libre DTC marketing work within regulatory constraints?
Abbott's DTC marketing for FreeStyle Libre must balance the compelling patient narrative about CGM's impact on diabetes management with FDA's requirements for medical device promotion. Patient testimonials can be used but must reflect clinical evidence, be typical of patient experience, and include required risk information. Comparative claims against Dexcom require head-to-head clinical substantiation. Claims about accuracy, sensor duration, and connectivity must be consistent with cleared labeling. Abbott navigates these constraints by developing DTC campaigns with regulatory review integrated into the creative development process, ensuring that messaging claims are cleared for use before media production and placement. The most effective FreeStyle Libre DTC campaigns build patient awareness and interest while directing patients to their healthcare providers for prescription, supporting the push-pull strategy.

What is the role of clinical publications in Alinity marketing?
Alinity's marketing to hospital and reference laboratory customers relies heavily on peer-reviewed clinical evidence demonstrating analytical performance – accuracy, precision, linearity, and interferences – for the specific assays on the platform. Clinical studies conducted by independent academic laboratory investigators at major medical centers and published in journals like Clinical Chemistry, JALM (Journal of Applied Laboratory Medicine), and Clinical Biochemistry provide the independent scientific validation that laboratory directors trust more than promotional materials. Abbott's medical affairs and commercial teams work to support independent investigators who want to evaluate Alinity platforms, and to facilitate timely publication of performance data that supports Abbott's commercial claims. Trade shows like AACC (American Association for Clinical Chemistry) and CAP (College of American Pathologists) are the primary professional marketing forums where Alinity scientific evidence is presented and discussed with laboratory opinion leaders.

How does Abbott approach the type 2 diabetes CGM market expansion?
The type 2 diabetes CGM market represents Abbott's largest growth opportunity for FreeStyle Libre, given that type 2 diabetes affects approximately 400 million people globally while type 1 affects fewer than 10 million. Abbott's type 2 expansion strategy requires changing physician prescribing behavior – many primary care physicians who manage the majority of type 2 patients have not historically prescribed CGM because it was perceived as appropriate only for insulin-dependent patients – and creating patient awareness that CGM technology exists and is beneficial even for type 2 patients on non-insulin regimens. The marketing challenge is building both physician willingness to prescribe and patient demand to request CGM simultaneously, in a market where payer coverage policies for type 2 CGM are also evolving and may require different coverage evidence than type 1 established benefits.

How does Abbott Nutrition manage the Ensure brand against grocery and clinical channels?
Ensure sells both through consumer grocery and pharmacy retail channels (where it competes against private label adult nutritional supplements and brand competitors like Boost from Nestle) and through clinical recommendation from physicians, dietitians, and hospital nutrition departments (where it is recommended as oral nutritional supplementation for patients with nutritional deficiencies, cancer, surgery recovery, and aging-related appetite loss). These two channels require different marketing approaches: consumer retail marketing builds brand awareness and shelf presence through consumer advertising and promotions, while clinical marketing builds the evidence base and healthcare provider recommendation through clinical studies on Ensure's nutritional outcomes, healthcare provider sampling and education programs, and hospital formulary inclusion. The clinical recommendation channel is particularly valuable because healthcare provider recommendations carry authority with patients that consumer advertising cannot replicate, creating a "clinical pull" that supports retail sales.